Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LQ083
- Development stage
- Preclinical
- Lead developer
- Novamab Biopharmaceuticals
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Oral
01
Overview
LQ083 is an orally administered VHH nanobody (single-domain antibody) targeting Tumor Necrosis Factor-like Ligand 1A (TL1A), developed by Novamab for the treatment of inflammatory bowel disease (IBD). TL1A is a member of the TNF superfamily that plays a key role in modulating inflammation and fibrosis by binding to its receptor, DR3. By neutralizing TL1A, LQ083 aims to reduce the mucosal inflammation and tissue remodeling associated with Crohn's disease and ulcerative colitis. The oral formulation is designed to provide local action within the gastrointestinal tract, potentially improving efficacy and safety compared to systemic biologics.
02
Targets
Beyond the preview
Go deeper on LQ083.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LQ083.